Immune regulation and cell metabolism in B cell subsets in patients with systemic lupus erythematosus
-
By
-
Masanobu Ueno
-
Satoshi Kubo
-
Yasuyuki Todoroki
-
Shingo Nakayamada
-
Yoshiya Tanaka
-
May 26, 2026
-
Clinical Scorecard: Regulation of Immunity and Metabolic Processes in B Cell Subpopulations Among Individuals with Systemic Lupus Erythematosus
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | Autoreactive B cells, immunometabolism, antibody production, cytokine secretion, antigen presentation |
| Target Population | |
| Care Setting | |
Key Highlights
- B cells play a central role in SLE through antibody production and cytokine secretion.
- Immunometabolism is crucial in regulating B cell activation and differentiation.
- Dysregulated metabolic control contributes to the pathogenesis of SLE.
- Current therapies include glucocorticoids and targeted B cell therapies like belimumab and rituximab.
- Emerging therapies aim to reduce dependence on glucocorticoids.
- Metabolic pathways influence B cell differentiation trajectories.
Guideline-Based Recommendations
Diagnosis
- Identify autoreactive B cells at transitional and mature naïve stages.
Management
- Utilize B-cell targeted therapies such as belimumab and rituximab.
- Identify novel biomarkers for treatment-refractory cases.
Monitoring & Follow-up
- Monitor disease activity and potential complications from therapies.
Risks
- Increased risk of infections and cardiovascular events from glucocorticoid therapies.
Patient & Prescribing Data
Individuals with refractory SLE
B-cell targeted therapies have shown clinical benefits and GC-sparing effects.
Clinical Best Practices
- Focus on immunometabolic pathways for therapeutic interventions.
- Implement regular monitoring for treatment-related complications.
- Educate patients on therapy risks and management strategies.
Related Resources & Content
